Pappalardi and colleagues identify a potent noncovalent DNMT1-selective inhibitor with improved tolerability and efficacy in preclinical AML models compared with clinically validated covalent pan-DNMT inhibitors.
- Melissa B. Pappalardi
- Kathryn Keenan
- Michael T. McCabe